TransMedics Group Inc. (TMDX)
TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to loss of $0.03 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.
